secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEOGENOMICS INC (NEO)
CIK:        0001077183
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001077183-22-000169
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeoGenomics Q3 revenue $129M (+6%); net loss widens to $37M, adjusted EBITDA -$12M
--------------------------------------------------------------------------------

- Revenue $129M (+6% YoY); Clinical Services $106M (+4%), Pharma Services $23M (+18%).
- Test volume -1% YoY; revenue per test +5% to $392.
- Net loss $37M (vs $20M loss in Q3 2021); prior year included $18M gain on Inivata investment.
- Adjusted EBITDA -$12M (vs -$3M); Adjusted Net Loss -$18M (vs -$10M).
- Cash and marketable securities $444M at quarter end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1077183/000107718322000169/0001077183-22-000169-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1077183/000107718322000169/neo-20221108.htm
  HTML page:      https://secwatch.observer/filing/0001077183-22-000169

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer